SNGX - ソリジェニックス (Soligenix Inc.) ソリジェニックス

 SNGXのチャート


 SNGXの企業情報

symbol SNGx
会社名 Soligenix Inc (ソリジェニックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Soligenix Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL) formulations of oral beclomethasone 17 21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation and its innate defense regulator (IDR) technology dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax its ricin toxin vaccine candidate OrbeShield its GI acute radiation syndrome (GI ARS) therapeutic candidate and SGX943 its melioidosis therapeutic candidate.   ソリジェニックスは米国のバイオ医薬品企業。後期の臨床段階で、がん治療法やワクチンの開発に従事。皮膚T細胞リンパ腫の治療に経口べクロメタゾン、胃腸障害の治療にニプロピオン酸塩、頭頚部がん治療に「Dusquetide(SGX942)」などを開発する。ワクチン部門ではリシン毒素ワクチン候補などの開発を行う。本社はニュ―ジャ―ジ―州プリンストン。   Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
本社所在地 29 Emmons Drive Suite C-10 Princeton NJ 08540 USA
代表者氏名 Christopher J. Schaber Christopher J. Schaber
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 609-538-8200
設立年月日 31778
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 16人
url www.soligenix.com
nasdaq_url https://www.nasdaq.com/symbol/sngx
adr_tso
EBITDA EBITDA(百万ドル) -7.47089
終値(lastsale) 1.8725
時価総額(marketcap) 33111116.0275
時価総額 時価総額(百万ドル) 25.10963
売上高 売上高(百万ドル) 5.95594
企業価値(EV) 企業価値(EV)(百万ドル) 20.86476
当期純利益 当期純利益(百万ドル) -7.03559
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Soligenix Inc revenues increased 23% to $2.8M. Net loss decreased 3% to $3.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General and administrative decrease of 14% to $1.4M (expense) Interest income net of expense increase from $10K to $50K (income) Research and development decrease of 1% to $3M (expense).

 SNGXのテクニカル分析


 SNGXのニュース

   Soligenix Inc Shares Close the Week 30.5% Lower - Weekly Wrap  2021/05/14 22:30:00 Kwhen Finance
Soligenix Inc (SNGX) shares closed this week 30.5% lower than it did at the end of last week. The stock is currently down 30.5% year-to-date, down 43.3% over the past 12 months, and down 56.4% over the past five years. This week, the Dow Jones Industrial Average fell 1.0%, and the S&P 500 fell 1.3%. Trading Activity Shares traded as high as $1.12 and as low as $0.85 this week.Shares closed 7e+1% below its 52-week high and 4% above its 52-week low.Trading volume this week was 43.6% lower than the 10-day average and 7.5% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -537.2% The company's stock price performance over the past 12 months lags the peer average by -358.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Graft-Versus-Host Disease (GVHD) Market | Share Analysis and Top Companies Neovii Biotech GmbH, Merck & Co., Inc., Astellas Pharma Inc., Soligenix, Inc., Mesoblast Ltd  2020/11/09 19:19:05 OpenPR
Graft-Versus-Host Disease (GVHD) Market is expected to rise gradually to an estimated value of USD 656.00 million by 2026, registering a CAGR of 6.05% in the forecast period of 2019-2026 with the annual sales of USD 410.00 million in the
   Soligenix Announces Recent Accomplishments And Second Quarter 2020 Financial Results  2020/08/14 11:00:00 PR Newswire
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing…
   TCOM, PII among premarket gainers  2020/07/28 12:16:54 Seeking Alpha
Eastman Kodak (NYSE:KODK) +190%. Spectrum Pharmaceuticals (NASDAQ:SPPI) +52% on positive poziotinib data in lung cancer. Soligenix (NASDAQ:SNGX) +44% on en
   Thinking about buying stock in Soligenix Inc, Ekso Bionics, SINTX Technologies, AIM ImmunoTech, or Nio Inc?  2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNGX, EKSO, SINT, AIM, and NIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Stock Alert: Soligenix Stock Up 45% In Pre Market  2020/04/16 09:29:00 RTT News
Shares of Soligenix Inc. (SNGX) are soaring over 45% in pre-market today, after the company announced an agreement for the exclusive worldwide license of CoVaccine HT, a novel vaccine adjuvant, from BTG Specialty Pharmaceuticals, a division of Boston Scientific Corp.
   Graft-Versus-Host Disease (GVHD) Market | Share Analysis and Top Companies Neovii Biotech GmbH, Merck & Co., Inc., Astellas Pharma Inc., Soligenix, Inc., Mesoblast Ltd  2020/11/09 19:19:05 OpenPR
Graft-Versus-Host Disease (GVHD) Market is expected to rise gradually to an estimated value of USD 656.00 million by 2026, registering a CAGR of 6.05% in the forecast period of 2019-2026 with the annual sales of USD 410.00 million in the
   Soligenix Announces Recent Accomplishments And Second Quarter 2020 Financial Results  2020/08/14 11:00:00 PR Newswire
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing…
   TCOM, PII among premarket gainers  2020/07/28 12:16:54 Seeking Alpha
Eastman Kodak (NYSE:KODK) +190%. Spectrum Pharmaceuticals (NASDAQ:SPPI) +52% on positive poziotinib data in lung cancer. Soligenix (NASDAQ:SNGX) +44% on en
   Thinking about buying stock in Soligenix Inc, Ekso Bionics, SINTX Technologies, AIM ImmunoTech, or Nio Inc?  2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNGX, EKSO, SINT, AIM, and NIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Stock Alert: Soligenix Stock Up 45% In Pre Market  2020/04/16 09:29:00 RTT News
Shares of Soligenix Inc. (SNGX) are soaring over 45% in pre-market today, after the company announced an agreement for the exclusive worldwide license of CoVaccine HT, a novel vaccine adjuvant, from BTG Specialty Pharmaceuticals, a division of Boston Scientific Corp.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ソリジェニックス SNGX Soligenix Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)